Neuropsychometric tests in cross sectional and longitudinal studies - A regression analysis of ADAS-cog, SKT and MMSE

Pharmacopsychiatry

Volumn 32, Issue 6, 1999, Pages 248-254

  Ihl, Ralf ^a   Grass Kapanke, B ^a   Janner M ^a   Weyer, G ^a  

^a UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AGED; ALZHEIMER DISEASE; ARTICLE; CLINICAL STUDY; CORRELATION FUNCTION; DEMENTIA; FEMALE; HUMAN; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; NEUROPSYCHOLOGICAL TEST; PREVALENCE; PRIORITY JOURNAL; PSYCHOMETRY; RATING SCALE; REGRESSION ANALYSIS; STATISTICAL ANALYSIS;

EID: 0032735883     PISSN: 01763679     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2007-991102     Document Type: Article

References (56)

1. Anthony LC, LeResche L, Niaz U, yon Korff MR, Folstein MF: Limits of the 'Mini-Mental State' as a screening test for dementia and delirium among hospital patients. Psychol Med 1982; 12: 397-408
2. Burch EAJ, Andrews SR: Comparison of two cognitive rating scales in medically ill patients. Int J Psychiatry Med 1987a; 17: 193-200
3. Butch EAJ, Andrews SR: Cognitive dysfunction in psychiatric consultation subgroups: Use of two screening tests. South Med J. 1987b; 80: 1079-1082
4. Burns A, Rossor M, Hecker J, Gauthier S, Petit H, Möller H-J, Rogers SL, Friedhoff LT, the international Donepezil Study Group: The effects of donepezil in Alzheimer's disease - Results from a multinational trial. Dement Geriatr Cogn Disord 1999; 10: 181-244
5. Christensen KJ, Mutchup KS, Norstrom S, et al: A cognitive battery for dementia. Development and measurement characteristics. Psychol Assessment 1991; 3: 168-174
6. Cockrell JR, Folstein MF: Mini Mental State Examination (MMSE). Psychopharmacol Bull 1988; 24: 689-692
7. Corey-Bloom J, Anand R, Veach J, for the ENA 713 B352 Study Group: A randomized trial evaluating the efficacy and safety of ENA713 (rivastigmine tartrate), a new acetylcholinesteraseinhibitor, in patients with mild to moderately severe Alzheimer's disease. Int J Geriatr Psychopharmacol 1998; 1: 55-65
8. Doraiswamy PM, Bieber F, Kaiser L, Krishnan KR, Reuning-Scherer J, Culanski B: The Alzheimer's disease assessment scale: Patterns and predictors of baseline cognitive performance in multicenter Alzheimer's disease trials. Neurology 1997; 48: 1511-1517
9. Erzigkeit H: The SKT-A Short Cognitive Performance Test as an instrument for the assessment of clinical efficacy of cognition enhancers. In: Diagnosis and Treatment of Senile Dementia. Edited by Bergener, M., 8. Reisberg, Berlin, Heidelberg, New York; Springer-Verlag 1989a: 164
10. Erzigkeit H: SKT - Ein Kurztest zur Erfassung von Gedächtnis- und Aufmerksamkeitsstörungen - Manual. Weinheim: Beltz-Test 1989b
11. Erzigkeit H: The development of the SKT project. In: Hindmarch I, Hippius H, Wilcock GK (eds.): Dementia: Molecules, Methods, and Measures. NY. John Wiley 1991
12. Erzigkeit H, Lehfeld H, Bratenstein HP: Stellenwert des SKT bei der beurteilung der klinischen wirksamkeit therapeutischer magnahmen. In: Lungershausen E (ed.): Demenz - Herausforderung für Forschung, Medizin und Gesellschaft. Berlin Heidelberg New York, Springer 1993
13. Farlow M, Gracon SI, Hershey LA, Lewis KW, Sodowsky CH, Dolan-Ureno J: A controlled trial of tacrine in Alzheimer's disease. JAMA 1992; 268: 2523-2529
14. Folstein MF, Folstein SE, McHugh PR: "MINI-MENTAL-STATE" a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975; 12: 189-198
15. Goodglass H, Kaplan E: The Assessment of Aphasia and Related Disorders. Philadelphia. Lea & Febiger 1972
16. Herrmann WM, Kern U, Röhmel J: On the effects of pyritinol on functional deficits of patients with organic mental disorders. Pharmacopsychiat 1986; 19: 378-385
17. Holtsberg PA, Pooh LW, Noble CA, Martin P: Mini-Mental State Exam Status of community-dwelling cognitively intact centenarians. International Psychogeriatrics 1995; 7: 417-427
18. Ihl R, Frölich L, Dierks T, Martin E, Maurer K: Differential validity of psychometric tests in dementia of the Alzheimer type. Psychiatr Res 1992; 44: 93-106
19. Ihl R, Kapanke B, Kretschmar C: Messinstrumente zur erfolgsbeurteilung tagesklinischer therapie bei patienten mit dementiellen erkankungen. Geriatrie Forschung 1997; 7: 139-143
20. Ihl R: Psychometric tests in Dementia of the Alzheimer type (DAT). Psychologische Beiträge 1998; 40: 55-65
21. Ihl R, Frölich L: Die Reisberg-Skalen GDS, BCRS, FAST. Weinheim: Beltz-Test 1991
22. Ihl R, Weyer G: Die Alzheimer's Disease Assessment Scale (ADAS). Weinheim: Beltz-Test 1993
23. Kanowski S, Kinzler E, Lehmann E, Schweizer A, Kuntz G: Confirmed clinical efficacy of actovegin in elderly patients with organic brain syndrome. Pharmacopsychiat 1995; 28: 125-133
24. Kanowski S, Herrmann WM, Stephan K, Wierich W. Hörr R: Proof of efficacy of ginkgo biloba special extract Egb 761 in outpatients suffering from mild to moderate primary degenerative dementia of the Alzheimer type or multi-infarct dementia. Pharmacopsychiat 1996; 29: 47-56
25. Kapanke G, Ihl R: Differentielle validität psychometrischer tests zur diagnose und schweregradmessung dementieller erkrankungen. Geriatrie Forschung 1997; 7: 85-90
26. Keßler J, Markowitsch HJ, Denzler P: Der Mini-Mental-Status-Test. Weinheim: Beltz-Test 1990
27. Kittner B, Rössner M. Rother M: Clinical trials in dementia with propentofylline. Cerebrovascular Pathology in Alzheimer's Disease. Annals of the New York Academy of Sciences. 1997; 826: 307-316
28. Knapp MJ, Knopman DS, Solomon PR, Pendlebury WW, Davis CS, Gracon SI, for the Tacrine Study Group: A 30 week randomized controlled trial of high-dose tacrine in patients with Alzheimer's disease. JAMA 1994; 271: 985-991
29. Kramer-Ginsberg E, Mohs RC, Aryan M. Lobel D, Silverman J. Davidson M, Davis KL: Clinical predictors of course for Alzheimer patients in a longitudinal study: A prelimininary report. Psychopharmacol Bull 1988; 24: 458-461
30. LeBars PL, Katz MM, Berman N, Itil TM, Freedman AM, Schatzberg AF. for the North American EGb Study Group: A placebo-controlled, double-blind, randomized trial of an extract of ginkgo biloba for dementia. JAMA 1997; 278: 1327-1332
31. Lehfeld H, H, Rudinger G, Rietz C, Heinrich C, Wied V, Fornazzari L, Pittas J. Hindmarch I. Erzigkeit H: Evidence of cross-cultural stability of the factor structure of the SKT short test for assessing deficits of memory and attention. International Psychogeriatrics 1997; 9: 139-153
32. Lehfeld H, Ihl R, Schweizer A, Steinwachs K. Frölich L, Gutzmann H, Blaha L, Kfigler C, Steiner I, Jentzsch J, Schmidt KH, Fischer S, Kagerbauer AM, Bürger G, Autenrieth T, Heinrifch C, Moesler T, Zimmermann P, Horn R, Kinzler F, Schubert H, Lehmann E, Erzigkeit H: Psychometrische schweregradbeurteilung bei dementiellen erkrankungen: Ein vergleich von MMST, ADAS, BCRS und SKT. Zeitschrift für Neuropsychologie (in press)
33. Lezak M: Neuropsychological assessment. 2nd ed. New York: Oxford University Press 1982
34. Marcusson J, Rather M, Kittner B, Rössner M, Smith RJ, Babic S, Folnegovic V, Möller HJ, Labs KH, on behalf of the European Propentofylline Study Group: A 12-month, randomized, placebo-controlled trial of propentofylline (HWA 285) in patients with dementia according to DSM III-R. Dement Geriatr Cogn Disord 1997; 8: 320-328
35. Maurer K, Ihl R, Dierks T, Frölich L: Clinical efficacy of ginkgo biloba special extract EGb761 in dementia of the Alzheimer type. J Psychiatr Res 1997; 31: 645-655
36. Mohs RC, Rosen WG, Davis KL: The Alzheimer's disease assessment scale: An instrument for assessing treatment efficacy. Psychopharmacol Bull 1983; 19: 448-450
37. Mohs RC, Cohen L: Alzheimer's Disease Assessment Scale. Psychopharmacol Bull 1988; 24: 627-628
38. Mohs RC, Davis KL: A signal detectability analysis of the effect of physostigmine on memory in patients with Alzheimer's disease. Neurobiol Aging 1982; 3: 105-110
39. Mohs RC: The Alzheimer's Disease Assessment Scale. International Psychogeriatrics 1996; 8: 195-203
40. Mohs RC, Knopman D, Peterson RC, Ferris SH, Ernesto C, Grundman M, Sano M, Bieliauskas L, Geldmacher D, Clark C Thal LJ: Development of cognitive instruments for use in clinical trials of antidmentia drugs: Additions to the Alzheimer's Disease Assessment Scale that broaden its scope. Alzheimer Disease and Associated Disorders 1997; 11: S13-521
41. Mohs RC. Cohen L: Alzheimer's Disease Assessment Scale (ADAS). Psychopharmacol Bull 1988; 24: 627-628
42. Morris JC, LaBarge E, Clark C, Hindman B, Heyman A, Fillenbaum G, Rogers H, Blass J, Karp H, Hill C, Mellits D. Rovner B, Brandt J, Crowdon J, Rosen J, Desclos G, Mohs R, Wiederholt W, Degosky S, Schmitt F, Huff J, Tariot P, Henderson V, Larson E, Canfield C, Hayox Z, van Belle G, Mortimer J: CERAD clinical and neuropsychological assessment of Alzheimer's disease: A preliminary report of standardized procedures and reliability. Neurology 1988a; 38 (Suppl. 1): 287
43. Morris JC, Mohs RC, Rogers H, Fillenbaum G, Heyman A: Consortium to establish a registry for Alzheimer's disease (CERAD) clinical and neuropsychological assessment of Alzheimer's disease. Psychopharmacol Bull 1988b; 24: 641-652
44. Neisser U: Visual search. Scientific American 1964; 210: 94-102
45. Oswald WD, Fleischmann UM: Der Nürnberger Altersinventar (NAI). Erlangen: Psychologisches Institut der Universität 1986
46. Reisberg B: Functional assessment staging (FAST). Psychopharmacol Bull 1988; 24: 653-659
47. Rogers SL, Friedhoff LT, the Donepezil Study Group: The efficacy and safety of donepezil in patients with Alzheimer's disease: results of a US multicentre, randomized, double-blind, placebo-controlled trial. Dementia 1996; 7: 293-303
48. Rogers SL, Farlow MR, Doody RS, Mohs R, Friedhoff LT, the Donepezil Study Group: A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Neurology 1998; 50: 136-145
49. Rosen WG, Mohs R, Davis KL: A new rating scale for Alzheimer's disease. Am J Psychiatry. 1984; 141: 1356-1364
50. Rösler M, Anand R. Cicin-Sain A, Gauthier S, Agid Y, Dal-Bianco P, Stahelin H, Hartman R, Gharabawi M, on behalf of the 8303 Exelon Study Group: Efficacy and safety of rivastigmine in patients with Alzheimer's disease: International randomised controlled trial. British Medical Journal 1999; 318: 633-640
51. Schwarb S, Köberle S, Spiegel R: The Alzheimer's Disease Assessment Scale: An instrument for early diagnosis of dementia? Int J Ger Psychiatr 1997; 3: 45-53
52. Stern RG, Molts RC Davidson M, et al: A longitudinal study of Alzheimer's disease: Measurement, rate and predictors of cognitive deterioration. Am J Psychiatry 1994; 151: 390-396
53. Stuss DR, Meiran N, Guzman DA, Lafleche G, Willmer J: Do long tests yield a more accurate diagnosis of dementia than short tests? A comparison of 5 neuropsychological tests. Arch Neurol 1999; 53: 1033-1039
54. Welsh K, Butters N, Hughes J, et al: Detection of abnormal memory decline in mild cases of Alzheimer's disease using CERAD neuropsychological measure. Arch Neurol 1991; 48: 278-281
55. Wilcock GK, Ashworth DL, Langfield JA, Smith PM: Detecting patients with Alzheimer's disease suitable for drug treatment: Comparison of three methods of assessment. Br J Gen Pract 1994; 44: 30-33
56. Yesavage JA, Poulsen SL, Sheikh E, Tanke E: Rates of change of common measures of impairment in senile dementia of the Alzheimer's type. Psychopharmacol Bull 1988; 24: 531-534